FDA Approves First Monthly Injectable Regimen for HIV
FRIDAY, Jan. 22, 2021 -- The U.S. Food and Drug Administration approved the first monthly injectable, complete regimen for HIV-infected adults, the agency announced Thursday.
Cabenuva (cabotegravir and rilpivirine, injectable formulation) is a complete regimen for treatment of HIV-1 and offers an alternative to the current daily oral antiretroviral regimen. It is indicated for patients who are virologically suppressed on a stable antiretroviral regimen and who have no history of treatment failure and no known or suspected resistance to cabotegravir or rilpivirine. With this approval, the FDA also approved Vocabria (cabotegravir, tablet formulation). Patients should take Vocabria with oral rilpivirine (Edurant) for one month before initiation of Cabenuva to ensure they can tolerate the medications before switching to the extended-release injectable formulation.
Approval was based on data from the Phase 3 ATLAS and FLAIR studies, two randomized, open-label, controlled clinical trials in 1,182 HIV-infected adults. Before initiating Cabenuva treatment, study participants were virologically suppressed (HIV-1 RNA <50 copies/mL). After 48 weeks of treatment, a comparable number of patients receiving Cabenuva and patients who continued their daily current antiretroviral regimen continued to show virologic suppression. Researchers found no clinically relevant change from baseline in CD4+ cell counts.
The most commonly reported adverse reactions were injection site reactions, fever, fatigue, headache, musculoskeletal pain, nausea, sleep disorders, dizziness, and rash.
Approval of Cabenuva and Vocabria was granted to ViiV Healthcare.
© 2021 HealthDay. All rights reserved.
Posted: January 2021
Read this next
FRIDAY, Feb. 26, 2021 -- Girls with higher total body fat (TBF) have differences in hormonal and clinical markers of puberty in late puberty, according to a study published online...
Here is what the editors at Physician's Briefing chose as the most important COVID-19 developments for you and your practice for the week of Feb. 22 to 26, 2021. This roundup...
FRIDAY, Feb. 26, 2021 -- Digital self-monitoring is associated with weight loss in behavioral interventions for overweight or obesity, according to a review published online Feb....
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.